Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
76.35
+0.55 (+0.73%)
Official Closing Price
Updated: 4:15 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Pfizer’s earnings growth trade at a deep discount, suddenly a buy
January 29, 2024
The healthcare sector is set to attract a new inflow of investment dollars, as seen in business activity and employment. Pfizer is the clear sector favorite
Via
MarketBeat
Topics
Economy
Exposures
Economy
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors
January 29, 2024
From
AstraZeneca
Via
Business Wire
3 Magnificent Stocks to Buy and Hold Forever
January 27, 2024
Many investors will want to consider owning these stocks for a long time.
Via
The Motley Fool
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
January 23, 2024
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.
Via
Benzinga
Exposures
Product Safety
Check Out What Whales Are Doing With AZN
January 17, 2024
Via
Benzinga
Evaluating AstraZeneca Against Peers In Pharmaceuticals Industry
January 09, 2024
Via
Benzinga
AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
January 22, 2024
From
AstraZeneca
Via
Business Wire
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
January 20, 2024
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech...
Via
Talk Markets
AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study
January 19, 2024
Explore results from AstraZeneca's EMERALD-1 Phase 3 trial on Imfinzi for unresectable hepatocellular carcinoma. Statistically significant improvement in progression-free survival with Imfinzi plus...
Via
Benzinga
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
January 19, 2024
From
AstraZeneca
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 16, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Are You Kidding Me? 3 Meme Stocks You Should Have Already Sold
January 15, 2024
Be sure to sell these meme stocks as they represent fundamentally weak businesses that will continue to erode in value.
Via
InvestorPlace
MarketBeat Week in Review – 1/8 - 1/12
January 13, 2024
Stocks drifted lower as the latest inflation numbers are dampening expectations for a rate cut; here are some of our top stories for your long weekend
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
January 12, 2024
Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed...
Via
Benzinga
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution
January 12, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
January 12, 2024
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.
Via
Investor's Business Daily
Oxford University Kicks off Human Study for AstraZeneca's COVID-19 Vaccine Technology in Nipah Virus Defense
January 11, 2024
Join the fight against Nipah virus! Oxford Vaccine Group launches groundbreaking ChAdOx1 NipahB vaccine trial, targeting the deadly virus. 51 participants aged 18-55. Funded by CEPI. Help combat Nipah...
Via
Benzinga
Exposures
COVID-19
AstraZeneca: Rebound in 2024 with double-digit earnings growth
January 11, 2024
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition
Via
MarketBeat
Exposures
COVID-19
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 08, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
Via
Investor Brand Network
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Are defensive sectors ready to outshine growth in 2024?
January 06, 2024
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead.
Via
MarketBeat
4 Superior Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
January 06, 2024
The growth-fueled Nasdaq Composite is 9% below its record high, meaning amazing deals are still hiding in plain sight.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
January 05, 2024
Key Takeaways: AstraZeneca will acquire Chinese cell therapy maker Gracell for up to $1.2 billion, representing an 86% premium to the company’s pre-announcement share price
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
January 04, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
January 04, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
7 Dividend-Paying Stocks To Add To Your Income Portfolio In 2024
January 03, 2024
These are the undervalued and fundamentally strong dividend-paying stocks to buy for high total returns in the next 24 to 36 months.
Via
InvestorPlace
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today
January 02, 2024
VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.